The stock of Corium International Inc (NASDAQ:CORI) is a huge mover today! The stock increased 5.86% or $0.26 on November 23, hitting $4.7. About 128,830 shares traded hands or 335.90% up from the average. Corium International Inc (NASDAQ:CORI) has risen 4.21% since April 22, 2016 and is uptrending. It has underperformed by 1.20% the S&P500.
The move comes after 6 months positive chart setup for the $96.80 million company. It was reported on Nov, 24 by Barchart.com. We have $4.94 PT which if reached, will make NASDAQ:CORI worth $4.84M more.
Analysts await Corium International Inc (NASDAQ:CORI) to report earnings on February, 13. They expect $-0.31 EPS, up 26.19% or $0.11 from last year’s $-0.42 per share. After $-0.42 actual EPS reported by Corium International Inc for the previous quarter, Wall Street now forecasts -26.19% EPS growth.
Corium International Inc (NASDAQ:CORI) Ratings Coverage
Out of 5 analysts covering Corium International (NASDAQ:CORI), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Corium International has been the topic of 9 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock of Corium International Inc (NASDAQ:CORI) has “Hold” rating given on Monday, August 31 by WBB Securities. The stock has “Buy” rating given by Needham on Tuesday, February 9. On Tuesday, August 25 the stock rating was downgraded by Zacks to “Buy”. On Wednesday, September 2 the stock rating was upgraded by Zacks to “Buy”. Needham maintained Corium International Inc (NASDAQ:CORI) on Monday, November 16 with “Buy” rating.
According to Zacks Investment Research, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.”
Insitutional Activity: The institutional sentiment decreased to 0.69 in 2016 Q2. Its down 0.04, from 0.73 in 2016Q1. The ratio turned negative, as 12 funds sold all Corium International Inc shares owned while 14 reduced positions. 8 funds bought stakes while 11 increased positions. They now own 18.39 million shares or 2.90% less from 18.94 million shares in 2016Q1.
The New York-based Needham Invest Mngmt Limited Liability Corporation has invested 0.2% in Corium International Inc (NASDAQ:CORI). Putnam Invests Limited Liability Corp has 325,000 shares for 0% of their US portfolio. Moreover, Millennium Mgmt Ltd has 0% invested in Corium International Inc (NASDAQ:CORI) for 26,675 shares. Wall Street Associates has 0.37% invested in the company for 265,700 shares. Geode Mngmt Lc last reported 65,455 shares in the company. Broadfin Cap Ltd Liability Corporation accumulated 0.65% or 1.92M shares. Tci Wealth Advsrs holds 0% or 162 shares in its portfolio. Northern Trust Corporation holds 0% or 18,633 shares in its portfolio. Rtw Investments Ltd Liability Co holds 852,961 shares or 1.01% of its portfolio. Tfs Cap Ltd Limited Liability Company holds 24,333 shares or 0.02% of its portfolio. Blackrock Inv Mngmt Limited, a New Jersey-based fund reported 2,270 shares. Victory Inc has 0% invested in the company for 4,060 shares. Panagora Asset Mgmt holds 0% or 18,778 shares in its portfolio. Goldman Sachs Grp, a New York-based fund reported 1.53M shares. Paloma Prtnrs holds 0% of its portfolio in Corium International Inc (NASDAQ:CORI) for 43,789 shares.
Another recent and important Corium International Inc (NASDAQ:CORI) news was published by Quotes.Wsj.com which published an article titled: “News Corium International Inc.CORI” on April 16, 2011.
CORI Company Profile
Corium International, Inc., incorporated on February 28, 2002, is a biopharmaceutical company. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules that are difficult to deliver in a transdermal dosage form. The Company’s Corplex and MicroCor platforms address some of the primary shortcomings of traditional transdermal drug delivery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.